Skip navigation
Skip navigation

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer

Snyder, Raymond; Boyle, Frances; Chan, Arlene; Craft, Paul; De Boer, Richard; Mainwaring, Paul; McCarthy, Nicole; Wilcken, Nick


Primary and acquired resistance to trastuzumab pose a therapeutic challenge when treating patients with HER2 (erbB-2)-positive locally advanced or metastatic breast cancer (MBC). The recent introduction of lapatinib (Tykerb/Tyverb, GlaxoSmithKline, Brentford, UK) provides a new management option for such patients. A prospective, randomized phase III clinical trial has confirmed that lapatinib in combination with capecitabine extends time to progressive disease in HER2-positive MBC, compared...[Show more]

CollectionsANU Research Publications
Date published: 2009
Type: Journal article
Source: Asia-Pacific Journal of Clinical Oncology
DOI: 10.1111/j.1743-7563.2009.01194.x


File Description SizeFormat Image
01_Snyder_Clinical_recommendations_for_2009.pdf454.35 kBAdobe PDFThumbnail

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator